oxybutynin has been researched along with Dementia in 13 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Dementia: An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study aimed to develop nanolipid carrier (NLC) loaded transdermal system of rivastigmine for bioavailability enhancement." | 5.51 | Optimization and characterization of rivastigmine nanolipid carrier loaded transdermal patches for the treatment of dementia. ( Chauhan, MK; Sharma, PK, 2019) |
| " Patients received stepwise pain treatment in which those who did not use analgesics were randomized to receive either paracetamol (3 g/day) or placebo tablets; those who already used pain treatment were allocated to buprenorphine transdermal system (max." | 5.27 | Effects of pain treatment on sleep in nursing home patients with dementia and depression: A multicenter placebo-controlled randomized clinical trial. ( Bjorvatn, B; Blytt, KM; Flo, E; Husebo, B, 2018) |
| " According to a predefined scheme for 8 weeks, all patients in the intervention group received individual daily pain treatment with acetaminophen, extended release morphine, buprenorphine transdermal patch, and/or pregabaline." | 5.19 | The response of agitated behavior to pain management in persons with dementia. ( Aarsland, D; Ballard, C; Cohen-Mansfield, J; Husebo, BS; Seifert, R, 2014) |
| "Pain medication significantly improved pain in the intervention group, with indications that acetaminophen also improved ADL function." | 5.19 | Impact of a stepwise protocol for treating pain on pain intensity in nursing home patients with dementia: a cluster randomized trial. ( Aarsland, D; Ballard, C; Corbett, A; Husebo, BS; Sandvik, RK; Seifert, R; Selbaek, G, 2014) |
| "Older adults receiving solifenacin and darifenacin in the 6 mo prior to diagnosis, and those receiving solifenacin, darifenacin, tolterodine, or fesoterodine in the year prior to diagnosis, have increased odds of incident dementia, compared with those receiving mirabegron." | 4.12 | Receipt of Overactive Bladder Drugs and Incident Dementia: A Population-based Case-control Study. ( Gomes, T; Herschorn, S; Jarvi, K; Juurlink, D; Matta, R; Nam, RK, 2022) |
| " Herein we report a patient with opioid-induced delirium associated with the administration of buprenorphine patches that was well below the indicated therapeutic range limit." | 3.79 | A case of topical opioid-induced delirium mistaken as behavioural and psychological symptoms of dementia in demented state. ( Ito, G; Kanemoto, K, 2013) |
| "Rivastigmine is an acetylcholine esterase inhibitor used in the treatment of dementia." | 3.78 | A fatal outcome after unintentional overdosing of rivastigmine patches. ( Hägg, S; Jönsson, AK; Lövborg, H, 2012) |
| "Elderly with dementia are prescribed opioids more frequent than elderly without." | 1.56 | The Use of Opioids and Antipsychotics in Elderly with Dementia - Have Opioids Replaced Antipsychotics in Treating Behavioral Symptoms in Dementia? ( Christensen, AN; Gasse, C; Jensen-Dahm, C; Waldemar, G, 2020) |
| "The present study aimed to develop nanolipid carrier (NLC) loaded transdermal system of rivastigmine for bioavailability enhancement." | 1.51 | Optimization and characterization of rivastigmine nanolipid carrier loaded transdermal patches for the treatment of dementia. ( Chauhan, MK; Sharma, PK, 2019) |
| "Type of menopause was not significantly associated with cognitive function." | 1.40 | Impact of a premature menopause on cognitive function in later life. ( Amieva, H; Ancelin, ML; Berr, C; Carrière, I; Ritchie, K; Rouaud, O; Ryan, J; Scali, J, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Matta, R | 1 |
| Gomes, T | 1 |
| Juurlink, D | 1 |
| Jarvi, K | 1 |
| Herschorn, S | 1 |
| Nam, RK | 1 |
| Welk, B | 1 |
| Richardson, K | 1 |
| Panicker, JN | 1 |
| Newman, DK | 1 |
| Sugiyama, T | 1 |
| Matsuda, H | 1 |
| Oonishi, N | 1 |
| Kiwamoto, H | 1 |
| Esa, A | 1 |
| Park, YC | 1 |
| Kurita, T | 1 |
| Uchida, A | 1 |
| Kunikata, S | 1 |
| Jensen-Dahm, C | 1 |
| Christensen, AN | 1 |
| Gasse, C | 1 |
| Waldemar, G | 1 |
| Srivastava, PK | 1 |
| Thakkar, HP | 1 |
| Blytt, KM | 1 |
| Bjorvatn, B | 1 |
| Husebo, B | 1 |
| Flo, E | 1 |
| Chauhan, MK | 1 |
| Sharma, PK | 1 |
| Husebo, BS | 2 |
| Ballard, C | 2 |
| Cohen-Mansfield, J | 1 |
| Seifert, R | 2 |
| Aarsland, D | 2 |
| Ito, G | 1 |
| Kanemoto, K | 1 |
| Ryan, J | 1 |
| Scali, J | 1 |
| Carrière, I | 1 |
| Amieva, H | 1 |
| Rouaud, O | 1 |
| Berr, C | 1 |
| Ritchie, K | 1 |
| Ancelin, ML | 1 |
| Sandvik, RK | 1 |
| Selbaek, G | 1 |
| Corbett, A | 1 |
| Lövborg, H | 1 |
| Jönsson, AK | 1 |
| Hägg, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Impact of Pain on Behavioural Disturbances in Patients With Moderate and Severe Dementia. A Cluster Randomized Trial[NCT01021696] | Phase 2/Phase 3 | 352 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for oxybutynin and Dementia
| Article | Year |
|---|---|
The cognitive effect of anticholinergics for patients with overactive bladder.
Topics: Benzhydryl Compounds; Benzofurans; Cholinergic Antagonists; Cognition; Cognitive Dysfunction; Dement | 2021 |
3 trials available for oxybutynin and Dementia
| Article | Year |
|---|---|
Effects of pain treatment on sleep in nursing home patients with dementia and depression: A multicenter placebo-controlled randomized clinical trial.
Topics: Acetaminophen; Adult; Aged; Analgesics; Buprenorphine; Dementia; Depressive Disorder; Double-Blind M | 2018 |
The response of agitated behavior to pain management in persons with dementia.
Topics: Acetaminophen; Aged, 80 and over; Analgesics; Buprenorphine; Delayed-Action Preparations; Dementia; | 2014 |
Impact of a stepwise protocol for treating pain on pain intensity in nursing home patients with dementia: a cluster randomized trial.
Topics: Acetaminophen; Activities of Daily Living; Aged; Aged, 80 and over; Analgesics; Buprenorphine; Clini | 2014 |
9 other studies available for oxybutynin and Dementia
| Article | Year |
|---|---|
Receipt of Overactive Bladder Drugs and Incident Dementia: A Population-based Case-control Study.
Topics: Aged; Canada; Case-Control Studies; Dementia; Humans; Muscarinic Antagonists; Solifenacin Succinate; | 2022 |
The MATRIX study: evaluating the data in older adults.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Attitude to Health; Dementia; Diapers, Ad | 2008 |
[Anticholinergic therapy of urinary incontinence and urinary frequency associated with the elderly--with special reference to dementia].
Topics: Aged; Aged, 80 and over; Butylamines; Dementia; Drug Administration Schedule; Drug Therapy, Combinat | 1993 |
The Use of Opioids and Antipsychotics in Elderly with Dementia - Have Opioids Replaced Antipsychotics in Treating Behavioral Symptoms in Dementia?
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Antipsychotic Agents; Behavioral Symptoms; Cross-Sectio | 2020 |
Vinpocetine loaded ultradeformable liposomes as fast dissolving microneedle patch: Tackling treatment challenges of dementia.
Topics: Animals; Cell Line, Transformed; Dementia; Female; Humans; Liposomes; Maze Learning; Microinjections | 2020 |
Optimization and characterization of rivastigmine nanolipid carrier loaded transdermal patches for the treatment of dementia.
Topics: Administration, Cutaneous; Animals; Blood Specimen Collection; Chromatography, High Pressure Liquid; | 2019 |
A case of topical opioid-induced delirium mistaken as behavioural and psychological symptoms of dementia in demented state.
Topics: Aged, 80 and over; Analgesics, Opioid; Buprenorphine; Confusion; Delirium; Dementia; Female; Halluci | 2013 |
Impact of a premature menopause on cognitive function in later life.
Topics: Aged; Aged, 80 and over; Cognition; Dementia; Estradiol; Estrogen Replacement Therapy; Estrogens; Fe | 2014 |
A fatal outcome after unintentional overdosing of rivastigmine patches.
Topics: Aged, 80 and over; Cholinesterase Inhibitors; Dementia; Drug Labeling; Drug Overdose; Fatal Outcome; | 2012 |